In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses
Viruses · 11.05.2023 · 15 (5) · 1154
DOI: 10.3390/v15051154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 11.05.2023. Verfasst von Takayuki Kuroda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shionogi & Co., Ltd., Osaka 561-0825, Japan. Hauptthemen laut MEDLINE: Influenza A virus, Influenza A Virus, H1N1 Subtype, Thiepins, Influenza, Human. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd..
Abstract (Originalsprache)
Although the prevalence of polymerase acidic (PA)/I38T strains of influenza virus with reduced susceptibility to baloxavir acid is low, there is a possibility of emergence under selective pressure. Furthermore, the virus may be transmitted between humans. We investigated the in vivo efficacy of baloxavir acid and oseltamivir phosphate against influenza A subtypes H1N1, H1N1pdm09, and H3N2, with PA/I38T substitution, at doses simulating human plasma concentrations. A pharmacokinetic/pharmacodynamic analysis was performed to strengthen the validity of the findings and the applicability in a clinical setting. Although the antiviral effect of baloxavir acid was attenuated in mice infected with PA/I38T-substituted viral strains compared with the wild type (WT), baloxavir acid significantly reduced virus titers at higher—but clinically relevant—doses. The virus titer reduction with baloxavir acid (30 mg/kg subcutaneous single dose) was comparable to that of oseltamivir phosphate (5 mg/kg orally twice daily) against H1N1 and H1N1pdm09 PA/I38T strains in mice, as well as the H3N2 PA/I38T strain in hamsters. Baloxavir acid demonstrated an antiviral effect against PA/I38T-substituted strains, at day 6, with no further viral rebound. In conclusion, baloxavir acid demonstrated dose-dependent antiviral effects comparable to that of oseltamivir phosphate, even though the degree of lung virus titer reduction was diminished in animal models infected with PA/I38T-substituted strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shionogi & Co., Ltd., Osaka 561-0825, Japan.
- Shionogi TechnoAdvance Research, Co., Ltd., Osaka 561-0825, Japan.
ORCID-Profile: Keiichi Taniguchi, Takao Shishido
Förderung
- Shionogi & Co., Ltd.
Zitieren
APA
Kuroda, T., Fukao, K., Yoshida, S., Oka, R., Baba, K., Ando, Y., Taniguchi, K., Noshi, T., & Shishido, T. (2023). In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses. Viruses, 15(5), 1154. https://doi.org/10.3390/v15051154
Vancouver
Kuroda T, Fukao K, Yoshida S, Oka R, Baba K, Ando Y, et al. In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses. Viruses. 2023;15(5):1154. doi:10.3390/v15051154
BibTeX
@article{Kuroda2023,
author = {Kuroda, Takayuki and Fukao, Keita and Yoshida, Shinpei and Oka, Ryoko and Baba, Kaoru and Ando, Yoshinori and Taniguchi, Keiichi and Noshi, Takeshi and Shishido, Takao},
title = {In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses},
journal = {Viruses},
year = {2023},
volume = {15},
number = {5},
pages = {1154},
doi = {10.3390/v15051154}
}
EUVIMED